The Sierra Leone National Infection Prevention and Control Guidelines were jointly developed and updated by the Ministry of Health and Sanitation in collaboration with the World Health Organization and the US Centers for Disease Control and Prevention.
No publication year indicated
The specific objectives of the plan are to:
- Scale up evidence-based, cost effective interventions through effective strategies within a HSS approach and provide equitable coverage with quality.
- Reduce neonatal mortality by improved home-based newborn ...care, early identification of sick newborns and improved access to institutional newborn care of adequate quality.
- Reduce common childhood illness related mortality (due to pneumonia and diarrhoea in all areas and malaria in endemic areas) by improving key family and community practices, community-based early diagnosis and management and referral care for complicated cases.
more
Nota científica
24 de abril de 2020
El desarrollo de inmunidad a un patógeno por infección natural es un proceso de varias etapas que suele producirse a lo largo de una o dos semanas. El organismo responde a una infección vírica de forma inmediata a través de una respuesta innata no específ...ica, en la que los macrófagos, los neutrófilos y las células dendríticas frenan el avance del virus y pueden incluso evitar que este provoque síntomas. A esta respuesta no específica le sigue una respuesta adaptativa en la que el organismo genera anticuerpos que se unen específicamente al virus. Estos anticuerpos son las proteínas denominadas inmunoglobulinas. El organismo también genera linfocitos T que reconocen y eliminan las células infectadas por el virus: es lo que se conoce como inmunidad celular. Esta respuesta adaptativa combinada puede eliminar el virus del organismo y, si la respuesta es suficientemente intensa, puede evitar el agravamiento de la enfermedad o la reinfección por el mismo virus. Este proceso se mide a menudo a través de la presencia de anticuerpos en la sangre.
more
This strategy, produced by IFRC, UNICEF and WHO, provides an overview of RCCE coordination approach and priorities across the different phases of the COVID-19 preparedness and response
Clinical management handbook
J Nepal Health Res Counc 2012 May;10(21):82-87
Survey report
Four health surveys were performed in Kutupalong Makeshift Settlment (KMS), Balukhali Makeshift Settlement (BMS), Kutupalong Makeshift Settlement Extension (KMS Extension) and Balukhali Makeshift Settlement Extension (BMS Extension). These sites were chosen to ensure that the health... status and conditions were measured in both the new settlements and the pre-existing settlements. The surveys measured current and retrospective mortality, the main morbidities affecting the population, global and severe acute malnutrition rates, vaccination coverage rates for key antigens and health-seeking behaviour. Simple random sampling was used with a recall period from 25th February 2017 until the date of interview (30th October to 12th November): approximately 260 days.
more
Overview
Learning objectives
• Name the general principles of essential care and practice.
• Name management principles of priority MNS conditions.
• Use effective communication skills in interactions with people with MNS conditions.
• Perform assessments for priority MNS conditions.
... Assess and manage physical health in MNS conditions.
• Know the impact of violence and gender-based violence on mental health.
• Provide psychosocial interventions to a person with a priority MNS condition and their
carer.
• Deliver pharmacological interventions as needed and appropriate in priority MNS
conditions considering special populations.
• Plan and perform follow-up for MNS conditions.
• Refer to specialists and links with outside agencies for MNS conditions as appropriate and
available.
• Promote respect and dignity for people with priority MNS conditions.
more
A case study from Bosnia and Herzegovina Eurasian Harm Reduction Network
The case study was prepared by Samir Ibisevic, President of PROI between March and June 2016 and edited by Graham Shaw.
EHRN is grateful to all who contributed to this document, especially: Dr. Serifa Godinjak, Chairperson... of Country Coordinating Mechanism; Dr. Zlatko Cardaklija, HIV Coordinator for the Federation of Bosnia and Herzegovina (BiH); Dr. Nesad Seremet, Head of the HIV program, United Nations Development Program in Bosnia and Herzegovina; Ms. Gyongyver Jakab, Fund Portfolio Manager, Eastern Europe and Central Asia and Ms. Natalya Bogach, Program Officer, The Global Fund to Fight AIDS, Tuberculosis and Malaria; Dr. Nermana Mehic–Basara, Director of the Institute for Addiction Diseases of Sarajevo Canton; Mr. Denis Dedajic, Director of the Association Margina from the Federation of BiH; Mr. Srdjan Kukolj, Director of Action Against AIDS from the Republic of Srpska.
more
Настоящее руководство «Клиническое ведение случаев COVID-19» базируется на
вышеуказанных стратегических приоритетах и адресовано клиницистам, участвующим в
оказа...ии помощи пациентам с подозреваемой или подтвержденной инфекцией COVID-19.
Оно не предназначено для того, чтобы заменить индивидуальное клиническое суждение или
консультацию специалиста, но призвано помочь клиническим работникам в обеспечении
наиболее эффективного ведения случаев. Повышенное внимание в настоящем руководстве
уделяется вопросам, касающимся особых и уязвимых групп населения, таких как дети,
пожилые люди и беременные женщины.
Interim guidance on clinical management COVID-19
more
Background paper 7
The Independent Panel for Pandemic Preparedness and Response
May 2021
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more